Immunic Inc (IMUX) Institutional Ownership & 13F Filings (Q2 2026)

IMUX ranks #5835 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

IMUX is a disclosed holding of Israel Englander (Millennium Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

57 institutions disclose a position in IMUX, but none treat it as a major bet — even Propel Bio Management, LLC, its most concentrated holder, allocates just 2.6% of its own portfolio to it.

IMUX is down 1.8% today, but institutions show net buying of $132.7M this quarter — a divergence between today's price move and the underlying institutional flow.

IMUX reported a net loss of $97.2M in its latest fiscal year.

• Not yet profitable — net loss of $97.2M in the latest fiscal year
• Net income improved year over year, from -$100.5M to -$97.2M
• Operating cash flow was negative, using $85.8M in cash
• Current ratio of 0.75x — below the conventional 1.5x liquidity buffer
• Total liabilities currently exceed total assets (negative shareholder equity)